Curis (CRIS) Stock Overview
A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
CRIS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Curis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.83 |
| 52 Week High | US$8.29 |
| 52 Week Low | US$1.02 |
| Beta | 3.66 |
| 1 Month Change | 1.67% |
| 3 Month Change | -13.68% |
| 1 Year Change | -57.83% |
| 3 Year Change | -91.68% |
| 5 Year Change | -91.76% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target
Aug 08
FDA And EMA Will Accelerate Emavusertib Clinical Trials
Feedback from regulatory bodies can expedite market entry for emavusertib, potentially accelerating revenue and competitive advantage in the CNS lymphoma space.Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS)
Apr 02Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30%
Apr 01Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Dec 29Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Nov 14Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%
Aug 07Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet
Aug 05Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 03Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry
Dec 26We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate
Nov 03We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely
Aug 05Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Apr 19Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?
Jan 02Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Sep 16Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study
Aug 18Curis: Asymmetric Risk And Reward
Jul 17Shareholder Returns
| CRIS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.3% | 4.7% | 1.3% |
| 1Y | -57.8% | -6.9% | 16.1% |
Return vs Industry: CRIS underperformed the US Biotechs industry which returned -6.9% over the past year.
Return vs Market: CRIS underperformed the US Market which returned 16.1% over the past year.
Price Volatility
| CRIS volatility | |
|---|---|
| CRIS Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CRIS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CRIS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 34 | Jim Dentzer | www.curis.com |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
Curis, Inc. Fundamentals Summary
| CRIS fundamental statistics | |
|---|---|
| Market cap | US$22.87m |
| Earnings (TTM) | -US$38.92m |
| Revenue (TTM) | US$11.41m |
Is CRIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRIS income statement (TTM) | |
|---|---|
| Revenue | US$11.41m |
| Cost of Revenue | US$38.17m |
| Gross Profit | -US$26.76m |
| Other Expenses | US$12.16m |
| Earnings | -US$38.92m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.11 |
| Gross Margin | -234.67% |
| Net Profit Margin | -341.25% |
| Debt/Equity Ratio | -215.6% |
How did CRIS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/18 16:51 |
| End of Day Share Price | 2025/08/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Curis, Inc. is covered by 25 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| Brian Skorney | Brean Capital |